Pressurised intraperitoneal aerosol chemotherapy (PIPAC) was introduced in Denmark in 2015. More than 100 Danish patients with peritoneal metastases (PM) have received PIPAC-directed treatment within the PIPAC-OPC1 and PIPAC-OPC2 trials. PIPAC-directed treatment is feasible and safe, and there are no occupational risks for the involved healthcare professionals. An objective tumour response is seen in two out of three patients, and the survival data warrant further evaluation in large-scale randomised trials in patients with PM from different primary tumours.
|Bidragets oversatte titel||Pressurised intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of peritoneal metastases|
|Tidsskrift||Ugeskrift for Laeger|
|Status||Udgivet - 14. okt. 2019|